278 related articles for article (PubMed ID: 29122990)
1. Expression of
Plešingerová H; Janovská P; Mishra A; Smyčková L; Poppová L; Libra A; Plevová K; Ovesná P; Radová L; Doubek M; Pavlová Š; Pospíšilová Š; Bryja V
Haematologica; 2018 Feb; 103(2):313-324. PubMed ID: 29122990
[TBL] [Abstract][Full Text] [Related]
2. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
3. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.
Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275
[TBL] [Abstract][Full Text] [Related]
4. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
5. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
[TBL] [Abstract][Full Text] [Related]
6. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
[TBL] [Abstract][Full Text] [Related]
7. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
8. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
9. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
Gonzalez D; Else M; Wren D; Usai M; Buhl AM; Parker A; Oscier D; Morgan G; Catovsky D
Haematologica; 2013 Feb; 98(2):274-8. PubMed ID: 22899580
[TBL] [Abstract][Full Text] [Related]
10. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
[TBL] [Abstract][Full Text] [Related]
11. CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
Perkins B; Showel M; Schoch L; Imus PH; Karantanos T; Yonescu R; Morsberger L; Ghiaur G; Gladstone DE; Jones RJ
Leuk Lymphoma; 2022 Jul; 63(7):1617-1623. PubMed ID: 35343368
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
Rigoni M; Riganti C; Vitale C; Griggio V; Campia I; Robino M; Foglietta M; Castella B; Sciancalepore P; Buondonno I; Drandi D; Ladetto M; Boccadoro M; Massaia M; Coscia M
Oncotarget; 2015 Oct; 6(30):29833-46. PubMed ID: 26284584
[TBL] [Abstract][Full Text] [Related]
13. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
14. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
Stamatopoulos B; Timbs A; Bruce D; Smith T; Clifford R; Robbe P; Burns A; Vavoulis DV; Lopez L; Antoniou P; Mason J; Dreau H; Schuh A
Leukemia; 2017 Apr; 31(4):837-845. PubMed ID: 27795555
[TBL] [Abstract][Full Text] [Related]
15. SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course.
Dezorella N; Katz BZ; Shapiro M; Polliack A; Perry C; Herishanu Y
Haematologica; 2016 Dec; 101(12):1553-1562. PubMed ID: 27443285
[TBL] [Abstract][Full Text] [Related]
16. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.
Stamatopoulos B; Smith T; Crompot E; Pieters K; Clifford R; Mraz M; Robbe P; Burns A; Timbs A; Bruce D; Hillmen P; Meuleman N; Mineur P; Firescu R; Maerevoet M; De Wilde V; Efira A; Philippé J; Verhasselt B; Offner F; Sims D; Heger A; Dreau H; Schuh A
Clin Cancer Res; 2018 Oct; 24(20):5048-5057. PubMed ID: 29945996
[No Abstract] [Full Text] [Related]
17. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N
Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases.
Zou Y; Fan L; Xia Y; Miao Y; Wu W; Cao L; Wu J; Zhu H; Qiao C; Wang L; Xu W; Li J
Cancer Med; 2018 May; 7(5):1689-1696. PubMed ID: 29573199
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
20. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.
Moia R; Patriarca A; Schipani M; Gaidano G
Cancer J; 2021 Jul-Aug 01; 27(4):266-274. PubMed ID: 34398553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
